Autoimmunity & Inflammation
Systemic Lupus Erythematosus
An autoimmune disease that can touch nearly every organ
Systemic lupus erythematosus is an autoimmune disease in which antibodies against the body's own nuclear material cause inflammation in the skin, joints, kidneys, blood, heart, lungs and brain. It mostly affects women in their reproductive years and carries a striking risk of premature heart disease, making long-term organ protection central to healthspan.
Also known as: SLE, lupus
By the numbers
50x
heart attack rate, women with lupus aged 35-44
Source: Manzi et al., Am J Epidemiol 1997
Animated explainer
See it happen inside the body
Educational animation based on published research. It is not medical advice and does not replace care from your own clinician.
Whole-body impact
The spillover effect
Chronic inflammation rarely stays in one place. Tap any organ to see how this condition reaches beyond its starting point.
Skin and scalp
The malar 'butterfly' rash, photosensitive rashes and discoid lesions are common. Discoid lupus on the scalp can cause permanent scarring hair loss, whereas diffuse non-scarring alopecia often regrows when disease is controlled.
Mouth and nose
Painless or painful ulcers on the palate, inner cheeks or nasal lining are a recognized classification feature of lupus.
Kidneys
Lupus nephritis, caused by immune-complex deposits in the glomeruli, can lead to protein in the urine, high blood pressure and, if untreated, kidney failure.
Lungs and heart lining
Pleurisy causes sharp chest pain with breathing, and pericarditis inflames the sac around the heart; both are classification features of SLE.
Coronary arteries
Premature coronary artery disease is a leading long-term cause of death; women with lupus aged 35-44 had over 50 times the heart attack rate of comparable Framingham Offspring women.
Blood and veins
Antiphospholipid antibodies increase the risk of deep vein thrombosis, stroke and pregnancy loss, and are part of the 2019 EULAR/ACR classification criteria.
Brain and nerves
Neuropsychiatric lupus ranges from headaches and cognitive fog to seizures, psychosis and delirium, the latter three counted in classification criteria.
Joints and blood cells
Inflammatory joint pain is very common, and lupus can lower white cells, platelets or red cells through immune destruction.
The biology
How it works
Lupus develops when dying cells are not cleared efficiently and their nuclear contents, such as DNA and histones, are exposed to the immune system. Plasmacytoid dendritic cells respond by producing type I interferon, which pushes the whole immune system into an antiviral alert state. B cells, supported by survival signals such as BAFF, mature into plasma cells that make anti-nuclear and anti-double-stranded DNA antibodies. These antibodies bind their targets to form immune complexes that lodge in the kidney, skin, joints and blood vessels, where they activate complement and inflammation. Some patients also make antiphospholipid antibodies that make blood more likely to clot. Because the drivers are systemic, lupus can flare in different organs at different times, which is why careful whole-body monitoring matters.
Healthspan
Why it matters for longevity
Survival in lupus has improved greatly, but the disease still erodes healthspan through cumulative organ damage, kidney involvement and early cardiovascular disease. The landmark Pittsburgh cohort showed that young women with lupus aged 35-44 had more than 50 times the expected rate of heart attack compared with women of similar age in the Framingham Offspring Study. Lupus nephritis remains a major driver of kidney failure and mortality, and long-term glucocorticoid exposure adds to bone, metabolic and vascular damage. Current EULAR guidance therefore emphasizes hydroxychloroquine for nearly all patients, minimizing steroids, early use of targeted therapies and aggressive management of cardiovascular and thrombotic risk.
The Four Quadrant Protocol™
How it connects across all four quadrants
Autoimmunity, metabolism, hormones and cellular health feed each other. This is why we treat the whole system, not one lab value.
Quadrant 02 Metabolic & Obesity Health
Inflammation, kidney disease and steroid exposure raise blood pressure, insulin resistance and lipid abnormalities, compounding lupus-related vascular risk.
Quadrant 03 Hormonal Optimization
Lupus affects women about nine times more often than men, flares can track with pregnancy and estrogen exposure, and antiphospholipid antibodies influence decisions about estrogen-containing therapy.
Quadrant 04 Regenerative & Cellular Health
Impaired clearance of dying cells is central to lupus, and new cell-based therapies such as CD19 CAR-T aim to 'reset' the B-cell compartment.
Research and longevity frontier
What science is testing now
Emerging therapies and active trials. Listed for education only. Many are not yet approved and are not offered as treatments here.
CD19 CAR-T cell therapy
Investigational (early-phase studies)
Engineered T cells that deplete CD19-positive B cells produced drug-free remission in 5 patients with refractory SLE, and a 15-patient follow-up series (SLE, myositis, systemic sclerosis) reported durable responses.
Anifrolumab (type I interferon receptor blockade)
FDA-approved 2021
In the TULIP-2 trial, blocking the type I interferon receptor improved global disease activity responses versus placebo in moderate to severe SLE.
Belimumab for lupus nephritis (BAFF targeting)
FDA-approved 2020 for lupus nephritis
In BLISS-LN, adding the anti-BAFF antibody belimumab to standard therapy improved two-year kidney response rates.
Voclosporin for lupus nephritis
FDA-approved 2021
In AURORA 1, this calcineurin inhibitor added to mycophenolate and low-dose steroids roughly doubled complete renal response at one year versus placebo.
Common questions
Frequently asked
Will lupus hair loss grow back?
It depends on the type. Diffuse thinning from active lupus is usually non-scarring and often regrows when inflammation is controlled, while discoid lesions on the scalp can destroy follicles and cause permanent scarring hair loss, so early treatment matters.
Why is heart disease such a concern in lupus?
Immune complexes, interferon and inflammation damage blood vessel walls, and kidney disease and steroids add further risk. Studies show heart attacks occur decades earlier than expected in some women with lupus, so blood pressure, lipids, smoking and clotting risk need active attention.
What are antiphospholipid antibodies?
They are antibodies that make blood more prone to clot, raising the risk of deep vein thrombosis, stroke and pregnancy complications. They are checked in people with lupus because results can change treatment decisions, including anticoagulation.
Peer-reviewed sources
Published evidence
Every claim on this page is drawn from peer-reviewed research, guidelines and registered clinical trials. Open any source to read the original.
cohort
Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-415.
guideline
Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15-29.
guideline
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400-1412.
RCT
Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117-1128.
RCT
Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211-221.
RCT
Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070-2080.
cohort
Mackensen A, Muller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124-2132.
cohort
Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med. 2024;390:687-700.
Educational website
fourquadrantprotocol.com is an educational resource. Content summarizes published research for learning purposes only. It is not medical advice, diagnosis or treatment, and it does not create a doctor-patient relationship. Always talk with your own clinician before changing any treatment. Questions: info@fourquadrantprotocol.com
Ready to look at the whole picture?
Work with Dr. Faisal Tahir to map your own four quadrants.
Book a consultation